North America Had the Largest Share in Leukapheresis Industry

The leukapheresis industry was valued at USD 71.4 million in 2022, it will touch USD 136.3 million, propelling at an 8.4% compound annual growth rate, by 2030.

The growth of the industry is attributed to the growing number of government initiatives to raise consciousness regarding cancer, the mounting prevalence of leukemia and other hematologic illnesses, increasing blood donations all over the world, rising research and development on leukopaks and their utilization in clinical research, and swiftly progressing technologies.

In 2022, the disposables category, based on offering, accounted for the largest share, and it will remain the largest in the years to come. This is attributed to the growing need for leukapheresis disposables due to the surging incidence of leukemia. Furthermore, the precise utilization of various disposables has the help in decreasing the threat of infections during blood transfusions.

Whereas, the devices category is expected to observe faster growth in the years to come, advancing at approximately 10% compound annual growth rate. This is mainly because of the increasing utilization of centrifugal apheresis instruments in blood donation centers for components separation of donated blood and in hospitals for therapy.

In 2022. the research category, based on application, accounted for the larger leukapheresis market share, of approximately 80%, and it will remain the largest in the years to come. This is mainly because of the increasing utilization of leukapheresis products for the production of cell-based immunotherapies, the mounting usage of leukapheresis-derived primary cells in pharmaceutical R&D, and the rising need for leukopaks in scientific research.

Whereas, the therapeutic category is expected to exhibit healthy growth in the years to come. This is because of the strong global network of businesses providing leukapheresis instruments and disposables for therapy. Furthermore, hospitals are continuously obtaining leukapheresis devices for patients’ treatments for various blood-borne illnesses.

In 2022, the North American leukapheresis industry held the largest share, of approximately 50%, and it will advance at a strong compound annual growth rate in the years to come. This is mainly because of the extensive R&D activities in the biotechnology and pharmaceutical sectors.

Moreover, the region also has a stronghold because of the existence of numerous healthcare providers and players, the higher risk of pandemics and transmittable diseases, and the numerous CAR T-cell therapy clinical trials.

APAC will observe the fastest growth in the years to come, owing to the enhanced healthcare infrastructure, increasing per capita income, surging elderly population, and mounting incidence of leukemia.

Furthermore, the regional industry is also driven by government initiatives to increase consciousness and encourage healthy lifestyles, along with technological enhancement in hematology. 

With the increasing government initiatives to raise consciousness regarding cancer and the surging prevalence of leukemia, the demand for leukapheresis will continue to increase in the years to come.